Solventum (SOLV) | Financial Analysis & Statements
Solventum Corp Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
2.0B
Gross Profit
1.0B
51.40%
Operating Income
93.0M
4.65%
Net Income
63.0M
3.15%
EPS (Diluted)
$0.36
Balance Sheet Metrics
Total Assets
14.3B
Total Liabilities
9.2B
Shareholders Equity
5.0B
Debt to Equity
1.83
Cash Flow Metrics
Operating Cash Flow
90.0M
Free Cash Flow
32.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Solventum Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 8.3B | 8.3B | 8.2B | 8.1B | 8.2B |
| Cost of Goods Sold | 3.9B | 3.7B | 3.7B | 3.4B | 3.2B |
| Gross Profit | 4.5B | 4.6B | 4.6B | 4.7B | 4.9B |
| Gross Margin % | 53.5% | 55.6% | 55.3% | 57.7% | 60.2% |
| Operating Expenses | |||||
| Research & Development | 739.0M | 775.0M | 759.0M | 767.0M | 766.0M |
| Selling, General & Administrative | 3.1B | 2.8B | 2.3B | 2.2B | 2.3B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 3.8B | 3.6B | 3.1B | 3.0B | 3.0B |
| Operating Income | 632.0M | 1.0B | 1.5B | 1.7B | 1.9B |
| Operating Margin % | 7.6% | 12.6% | 18.0% | 20.8% | 23.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 347.0M | 367.0M | - | - | - |
| Other Non-Operating Income | 1.4B | -64.0M | -570.0M | -1.0M | 3.0M |
| Pre-tax Income | 1.7B | 605.0M | 910.0M | 1.7B | 1.9B |
| Income Tax | 157.0M | 127.0M | 218.0M | 349.0M | 422.0M |
| Effective Tax Rate % | 9.2% | 21.0% | 24.0% | 20.6% | 22.4% |
| Net Income | 1.6B | 478.0M | 692.0M | 1.3B | 1.5B |
| Net Margin % | 18.7% | 5.8% | 8.4% | 16.5% | 17.9% |
| Key Metrics | |||||
| EBITDA | 1.1B | 1.5B | 2.0B | 2.3B | 2.5B |
| EPS (Basic) | $8.94 | $2.77 | $4.01 | $7.79 | $8.47 |
| EPS (Diluted) | $8.88 | $2.76 | $4.01 | $7.79 | $8.47 |
| Basic Shares Outstanding | 174100000 | 173200000 | 172466022 | 172466022 | 172466022 |
| Diluted Shares Outstanding | 174100000 | 173200000 | 172466022 | 172466022 | 172466022 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Solventum Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 878.0M | 762.0M | 600.0M | 61.0M | 91.0M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.0B | 1.0B | 1.1B | 1.2B | 1.2B |
| Inventory | 1.1B | 965.0M | 869.0M | 873.0M | 813.0M |
| Other Current Assets | 557.0M | 293.0M | 154.0M | 126.0M | 108.0M |
| Total Current Assets | 3.9B | 3.2B | 2.9B | 2.2B | 2.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | - | 29.0M | 33.0M |
| Goodwill | 14.0B | 15.3B | 16.0B | 16.1B | 17.0B |
| Intangible Assets | 2.6B | 2.5B | 2.9B | 3.3B | 3.7B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 814.0M | 665.0M | 558.0M | 358.0M | 253.0M |
| Total Non-Current Assets | 10.4B | 11.2B | 11.5B | 11.4B | 11.9B |
| Total Assets | 14.3B | 14.5B | 14.4B | 13.6B | 14.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 687.0M | 618.0M | 468.0M | 348.0M | 320.0M |
| Short-term Debt | - | 200.0M | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 634.0M | 378.0M | 729.0M | 171.0M | 187.0M |
| Total Current Liabilities | 3.1B | 2.7B | 1.8B | 1.3B | 1.4B |
| Non-Current Liabilities | |||||
| Long-term Debt | 5.0B | 7.8B | 8.3B | - | - |
| Deferred Tax Liabilities | 164.0M | 225.0M | 239.0M | 215.0M | 218.0M |
| Other Non-Current Liabilities | 546.0M | 410.0M | 224.0M | 235.0M | 245.0M |
| Total Non-Current Liabilities | 6.1B | 8.8B | 9.2B | 541.0M | 610.0M |
| Total Liabilities | 9.2B | 11.5B | 11.0B | 1.9B | 2.0B |
| Equity | |||||
| Common Stock | 2.0M | 2.0M | 2.0M | - | - |
| Retained Earnings | 1.8B | 242.0M | - | - | - |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 5.0B | 3.0B | 3.4B | 11.7B | 12.1B |
| Key Metrics | |||||
| Total Debt | 5.0B | 8.0B | 8.3B | 0 | 0 |
| Working Capital | 723.0M | 546.0M | 1.1B | 920.0M | 783.0M |
Balance Sheet Composition
Solventum Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.6B | 479.0M | 1.3B | 1.3B | 1.5B |
| Depreciation & Amortization | 489.0M | 555.0M | 561.0M | 578.0M | 597.0M |
| Stock-Based Compensation | 161.0M | 112.0M | 39.0M | 37.0M | 38.0M |
| Working Capital Changes | -151.0M | 725.0M | 126.0M | -202.0M | 67.0M |
| Operating Cash Flow | 1.8B | 1.7B | 1.9B | 1.6B | 2.1B |
| Investing Activities | |||||
| Capital Expenditures | -379.0M | -380.0M | -290.0M | -251.0M | -277.0M |
| Acquisitions | 3.2B | 0 | 60.0M | 0 | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | 0 | - |
| Investing Cash Flow | 2.8B | -380.0M | -230.0M | -253.0M | -278.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 8.3B | - | - | - |
| Debt Repayment | -3.1B | -300.0M | - | 0 | - |
| Financing Cash Flow | -3.1B | -240.0M | -1.6B | -1.5B | -2.0B |
| Free Cash Flow | -10.0M | 805.0M | 1.6B | 1.4B | 1.9B |
| Net Change in Cash | 1.6B | 1.1B | 148.0M | -98.0M | -110.0M |
Cash Flow Trend
Solventum Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
7.78
Forward P/E
9.83
Price to Book
2.37
Price to Sales
1.44
PEG Ratio
0.07
Profitability Ratios
Profit Margin
18.69%
Operating Margin
7.01%
Return on Equity
38.86%
Return on Assets
2.94%
Financial Health
Current Ratio
1.23
Debt to Equity
103.94
Beta
0.77
Per Share Data
EPS (TTM)
$8.88
Book Value per Share
$29.10
Revenue per Share
$47.82
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SOLV | 12.0B | 7.78 | 2.37 | 38.86% | 18.69% | 103.94 |
| Intuitive Surgical | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
| ResMed | 32.0B | 21.69 | 5.06 | 25.68% | 27.53% | 13.41 |
| West Pharmaceutical | 22.1B | 40.99 | 6.94 | 19.13% | 16.85% | 10.73 |
Financial data is updated regularly. All figures are in the company's reporting currency.






